





RealRate

# PHARMACEUTICAL 2020

Global Blood Therapeutics Inc.  
Rank 117 of 358



The relative strengths and weaknesses of Global Blood Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Global Blood Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 57% points. The greatest weakness of Global Blood Therapeutics Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 49% points.

The company's Economic Capital Ratio, given in the ranking table, is 144%, being 108% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	627,997
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	71,453
Liabilities, Non-Current	145,952
Other Assets	140,989
Other Compr. Net Income	802
Other Expenses	283,571
Other Liabilities	0
Other Net Income	14,697
Other Revenues	2,108
Property and Equipment	27,113
Research and Development	0
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	796,099
Liabilities	217,405
Expenses	283,571
Revenues	2,108
Stockholders Equity	578,694
Net Income	-266,766
Comprehensive Net Income	-266,365
Economic Capital Ratio	144%